PKN Stock Chart & Stats
€110.80
-€1.46(-1.50%)
At close: 4:00 PM EDT
€110.80
-€1.46(-1.50%)
Day’s Range― - ―
52-Week Range€69.64 - €150.70
Previous CloseN/A
Volume0.00
Average Volume (3M)41.00
Market Cap
€15.63B
Enterprise Value€15.02B
Total Cash (Recent Filing)€1.02B
Total Debt (Recent Filing)€3.34B
Price to Earnings (P/E)74.8
Beta0.50
Next Earnings
Nov 03, 2026EPS Estimate
1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.10
Shares Outstanding111,586,400
10 Day Avg. Volume48
30 Day Avg. Volume41
Financial Highlights & Ratios
PEG Ratio-3.41
Price to Book (P/B)1.52
Price to Sales (P/S)3.85
P/FCF Ratio21.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€127.12Price Target Upside14.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)4.77
Revenue Forecast (FY)€2.54B
Bulls Say, Bears Say
Bulls Say
Diagnostics GrowthDiagnostics is showing broad, sustained demand across reproductive health and immunodiagnostics, providing a durable growth engine within the portfolio. This strength can support recurring testing-related consumables and services while offsetting weaker areas of the business.
Cash Generation And DeleveragingStrong free cash flow conversion gives Revvity internal funding for product investment, acquisitions and debt reduction. Retiring debt while targeting net leverage near 2x should improve financial flexibility and reduce balance-sheet constraints over the next several quarters.
Instrument And Software InnovationDouble-digit screening order growth, a multi-year-high backlog and expanding software capabilities indicate strengthening customer adoption of Revvity workflows. A broader instrument, software and informatics ecosystem can deepen customer relationships and support recurring revenue.
Bears Say
Margin Compression And Earnings VolatilityAlthough current profitability is solid, margins remain well below earlier-cycle levels and historical earnings have been uneven. This limits the predictability of long-term earnings power and leaves less operating cushion if demand or business mix becomes less favorable.
Signals Software WeaknessThe sharp Signals decline shows that software revenue remains exposed to contract timing and comparison effects, despite management expecting recovery. Continued volatility could make growth less predictable and weaken the contribution of a potentially recurring, high-value business.
China Immunodiagnostics DivestitureExiting China Immunodiagnostics may streamline the portfolio, but it also removes an established revenue contribution and reflects structural difficulty in that market. Until closing, the business remains in reported results, creating a prolonged transition in geographic mix.
Revvity News
PKN FAQ
What was Revvity’s price range in the past 12 months?
Revvity lowest stock price was €69.64 and its highest was €150.70 in the past 12 months.
What is Revvity’s market cap?
Revvity’s market cap is €15.63B.
When is Revvity’s upcoming earnings report date?
Revvity’s upcoming earnings report date is Nov 03, 2026 which is in 2 days.
How were Revvity’s earnings last quarter?
Revvity released its earnings results on Aug 04, 2026. The company reported €1.258 earnings per share for the quarter, beating the consensus estimate of €1.083 by €0.175.
Is Revvity overvalued?
According to Wall Street analysts Revvity’s price is currently Undervalued.
Does Revvity pay dividends?
Revvity does not currently pay dividends.
What is Revvity’s EPS estimate?
Revvity’s EPS estimate is 1.16.
How many shares outstanding does Revvity have?
Revvity has 111,586,400 shares outstanding.
What happened to Revvity’s price movement after its last earnings report?
Revvity reported an EPS of €1.258 in its last earnings report, beating expectations of €1.083. Following the earnings report the stock price went down -0.737%.
Which hedge fund is a major shareholder of Revvity?
Currently, no hedge funds are holding shares in DE:PKN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revvity Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€127.12 (14.73% Upside)
€127.12 (14.73% Upside)
Blogger Sentiment
Neutral
DE:PKN Sentiment 78%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
72.91%
12-Months-Change
Fundamentals
Return on Equity
3.27%
Trailing 12-Months
Asset Growth
-2.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Revvity
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
PKN Company Deck
PKN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a generally positive operational and financial picture: revenue and EPS beat with upgraded full-year guidance, strong Diagnostics performance, accelerating high-content instrument orders and robust cash flow and balance sheet improvements. Key near-term weaknesses include a sizable decline in Signals software revenue this quarter, some production/timing constraints that shifted instrument revenue into Q3, and portions of the quarter's outperformance tied to one-time tariff refunds and tax timing. Management plans reinvestments of a portion of one-time benefits while highlighting new software capabilities and AI-driven demand as multi-year growth drivers—though the AI opportunity is still early and not fully quantifiable.View all DE:PKN earnings summariesPKN Revenue Breakdown
50.11% Life sciences
49.89% Diagnostics

PKN Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€127.12
▲(14.73% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month









